Plymouth Meeting’s Inovio Pharmaceuticals received good news from the preliminary results of its expanded stage phase I study of EBOV-001, the company’s Ebola vaccine candidate.

The expanded study focused on examining different regimens of its Ebola DNA vaccine. The results across both stages of the trial demonstrated that 95 percent of participants in the study generated an antibody immune response specific to Ebola. In addition, the antibody was comparable or even superior to those from viral vector-based Ebola vaccines as, so far, it has fewer side-effects.

[uam_ad id=”51712″]

Advertisement

The study also showed that Inovio’s DNA vaccine is a potentially viable response to the deadly worldwide disease. This is due to its relatively quick production cycle and the ability to continue to boost immune responses and protection with repeat doses.

“This response rate mirrors the high response rates we recently reported from our MERS and Zika clinical studies, reinforcing Inovio’s ability to rapidly design and construct vaccines against emerging global infectious diseases,“ said Dr. J. Joseph Kim, Inovio’s President & CEO.

He added that these strong results from the 200 subjects together with positive preliminary preclinical data from several animal species have opened the path for the company to meet with regulators later this year to discuss licensing the vaccine.

[uam_ad id=”51711″]

Top photo credit: Radio Alfa Vaccino influenzale via photopin (license)